This information is intended for healthcare professionals based in Ireland.

Dosing in NVAF

Simple dosing guidance for NVAF patients

The recommended dose of ELIQUIS® is 5 mg taken orally twice daily (BD) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).1

  • 95.3% of ELIQUIS® patients received a 5 mg BD dose in the ARISTOTLE trial.2
  • Prior to initiating ELIQUIS®, liver function testing should be performed.1

  Dosing for ELIQUIS® in NVAF

dosing for eliquis (apixaban) in nvaf image

Adapted from reference 1.

Missed dose

If a dose is missed, the patient should take ELIQUIS® as soon as they remember, and then continue to follow the regular dosing schedule.

For full information on dosing guidance, please visit SmPC.

Clear dosing guidance for special populations

The recommended dose of ELIQUIS® is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥1.5 mg/dl (133 micromole/l).1

  • 4.7% of ELIQUIS® patients received a 2.5 mg BD dose in the ARISTOTLE trial2
  • Consistent safety and efficacy outcomes were demonstrated in the ARISTOTLE sub group analyses across both doses of ELIQUIS® 2
  • ELIQUIS® is not recommended in patients with CrCl <15 ml/min or in patients undergoing dialysis1
  • Approximately 27% of ELIQUIS® is renally excreted1

  Criteria for ELIQUIS® 2.5 mg BD dosing

criteria for eliquis (apixaban) 2.5 mg bd dosing image

Adapted from reference 1

Risk Minimisation Materials

The Eliquis (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications as an aid to prescribing, in particular they are aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk. Printed copies of these educational materials may be obtained by contacting the Bristol-Myers Squibb Medical Information Department (telephone: 1800 749 749; e-mail: medical.information@bms.com). Alternatively, electronic copies can be accessed via the HPRA website at http://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine.

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.